Nowhere is patent protection more important than in the pharmaceutical industry. Our pharmaceutical patent practice is second to none, and we have a concentration of pharmaceutical patent expertise envied by our competitors. We represent many of the world's major pharmaceutical companies, including Amgen, Astellas, AstraZeneca, Bausch & Lomb, Bristol-Myers Squibb, Daiichi Sankyo, Genzyme, GlaxoSmithKline, Kyowa Hakko, Merck, Novartis, Sepracor, Sanofi-Aventis and UCB.
These clients repeatedly entrust us with cases involving their most valuable intellectual property, the patents on blockbuster drugs that are vital to their continued growth. We have been involved in representing branded pharmaceutical companies in defending against generic challengers for more than 20 years and we believe that we have handled more ANDA-based litigations than any other firm. We have advised clients, not only on responding to an ANDA challenge after one is received, but also in preparing well in advance to meet such challenges. We have litigated patents in virtually every field of medicine, including such diverse subjects as anti-infectives, antipsychotics, oncologics, cardiovascular drugs, fertility control, hormone replacement, anti-ulcer drugs, antiinflammatories, anti-epileptics and anti-virals. Our staff of lawyers have experience and training in all aspects of chemistry and pharmaceuticals.
Related Information
Representative Cases
In re Rosuvastatin Calcium Patent Litigation 08-MD-01949
Novartis Pharmaceuticals Corporation and Novartis Pharma AG v. Teva Pharmaceuticals USA Inc D.N.J. 2009
Sanofi-Aventis U.S. LLC, Sanofi-Aventis, and Debiopharm S.A. v. Sandoz, Inc. et al. Fed. Cir. 2009
Unigene Labs., Inc., et al. v. Apotex, Inc., et al. S.D.N.Y., 2009
Daiichi Sankyo Company, Ltd., et al. v. Mylan Pharmaceuticals, Inc. et al. D.N.J., 2009
Sanofi-Synthelabo, et al. v. Apotex, Inc. Fed. Cir. 2008
Merck & Co., Inc. v. Apotex Inc., et al. Fed. Cir. 2008
AstraZeneca Pharmaceutical LP et al. v. Teva Pharmaceuticals USA, Inc, et al. D.N.J. 2008
Merck & Co., Inc. v. Apotex Inc., et al. D.N.J. 2007
Sanofi-Synthelabo, et al. v. Apotex Inc. S.D.N.Y. 2007
Merck & Co, Inc. v. Hi-Tech Pharmacal Co., Inc. Fed. Cir. 2007
Adams Respiratory Operations, Inc. v. Mutual Pharmaceutical Co., et al. E.D.Pa. 2007
Astellas Pharma Inc., et al. v. Ranbaxy Inc., et al D.N.J. 2007
Sanofi-Synthelabo, Sanofi-Synthelabo Inc. and Bristol-Myers Squibb, sanofi Pharmaceuticals Holding Partnership v. Apotex Inc. and Apotex Corp. Fed. Cir. and S.D.N.Y 2006
UCB Societe Anonyme & UCB Pharma Inc. v. Mylan Laboratories, Inc. et al N.D. GA 2006
Teva Pharmaceuticals USA, Inc. v. Novartis D.N.J. 2005
Mylan Pharmaceuticals Inc. v. Merck & Co., Inc. M.D. PA 2005
Eli Lilly and Company, et al. v. Teva Pharmaceuticals USA, Inc. Fed. Cir. 2005
Pfizer, Inc. and Warner-Lambert Company v. Ranbaxy Pharmaceuticals and Teva Pharmaceuticals D.N.J. 2005
Eli Lilly and Company, et al. v. Teva Pharmaceuticals USA, Inc. S.D. Indiana 2004
SmithKline Beecham Corporation v. Teva Pharmaceuticals USA, Inc. D.N.J. 2004
The Regents of the University of Michigan and Repligen Corp. v. Bristol-Myers Squibb Fed. Cir. 2004
Warner-Lambert Company v. Teva Pharmaceuticals Inc. D.N.J. 2004
Novartis Pharmaceuticals Corp. v. Apotex Corp. S.D.N.Y. 2004
Housey Pharmaceuticals v. Bristol-Myers Squibb Co. Fed. Cir. 2004
University of Rochester v. G.D. Searle and Co., Inc., Pfizer Inc., Monsanto Co., and Pharmacia Corp. Fed. Cir. 2004
Warner-Lambert Company v. Teva Pharmaceuticals USA D.N.J. 2003
The Regents of the University of Michigan and Repligen Corp. v. Bristol-Myers Squibb Co. E.D. Mich. 2003
AstraZeneca AB, et al. v. Mutual Pharmaceutical Co., Inc. E.D.Pa 2003
Bristol-Myers Squibb Company v. Rhone-Poulenc Rorer, Inc. et. al. Fed. Cir. 2003
University of Rochester v. G.D. Searle & Co., Inc., Pfizer Inc., Monsanto Co., and Pharmacia Corp. W.D.N.Y. 2003
In re Omeprazole Patent Litigation S.D.N.Y. 2002
Warner-Lambert Co. v. Teva Pharmaceuticals USA, D.N.J. 2002
AstraZeneca AB, et al. v. Mutual Pharmaceutical Co., Inc. E.D.Pa. 2002
Schwartz Pharma Inc., Schwartz Pharma AG and Warner-Lambert Co. v. Teva Pharmaceuticals USA D.N.J. 2002
FTAP Holdings, Inc. et.al. V. OWL Pharmaceuticals LLC et.al. N.D. Ohio 2002
Housey Pharmaceuticals v. Bristol-Myers Squibb Co. D.Del 2002
Allergan v. Bausch & Lomb and Alcon C.D. Cal., 2002
Yamanouchi Pharmaceutical Co., Ltd. v. Danbury Pharmacal, Inc. Fed. Cir. 2000
Bausch & Lomb, Inc. v. Alcon Laboratories, Inc. W.D.N.Y. 1999
Grain Processing Corp. v. American Maize-Products Co. Fed. Cir. 1998
Publications
Bilski: the life sciences angle Intellectual Asset Management
February 2010
Extending the 30-Month FDA Stay in an ANDA Litigation Fitzpatrick Case Update
July 9, 2009
Variations on a Theme: Five Approved Abbreviated Approval Pathways for Biologics Bloomberg Health Law
April 2009
Significance of Takeda v. Mylan IP LAW 360
March 6, 2009
Hatch-Waxman Safe Harbor Construed in 'Merck v. Integra' The New York Law Journal
July 8, 2005
Doctrine of Inherent Anticipation is Clarified The National Law Journal
December 8, 2003
Enablement in the Spotlight The National Law Journal
June 16, 2003
Events
4th Annual Paragraph IV Disputes: Expert Insights on Hatch-Waxman Litigation Strategies for Brand Names and Generics American Conference Institute
April 27-28, 2010
5th Annual Conference on Corporate Intellectual Property in China 2010 LexisNexis
April 22-23, 2010
2nd Annual Paragraph IV on Trial Conference American Conference Institute
November 12-13, 2009
5th Annual Developing IP Strategies for Crystalline Forms Conference IQPC
November 9-11, 2009
Recent Development in Parties' Obligations in a Hatch-Waxman Act Litigation ACI's 10th Anniversary Maximizing Pharmaceutical Patent Life Cycles
October 7, 2009
Pharmaceutical Patent Protection And Regulation: A Global Perspective Second Beijing International Pharmaceutical & Chemical Intellectual Property Forum
August 4-7th, 2009
Navigating the Challenges of ANDA Disputes Law 360
July 28, 2009
2008 PLAVIX Decisions by the U.S. Court of Appeals for the Federal Circuit and the Supreme Court of Canada NJIPLA Patent Litigation Seminar
March 9, 2009
The Impact of KSR On Pharma/Bio Patent Obviousness C5 Pharma & Bio Patent Litigation
February 17-18, 2009
Highlighting In-Depth Interference Practices, Patent Life Cycle Management and Litigation Tactics IQPC's 2nd Annual Patent Strategies for the Pharma, Biotech and Medical Device Industries
July 15-16, 2008
Best Practices for Evaluating Your Infringement Risk and Interpreting the Claims C5's 5th Annual International Freedom to Operate Forum
June 10, 2008
Bioequivalence: What Lawyers Need to Know American Conference Institute’s FDA Boot Camp: Basic Training for Products Liability and Patent Lawyers
May 30, 2008
Managing the Risks Associated with Injunctions and At-Risk Launches During Litigation and Appeal American Conference Institute’s 2nd Annual Paragraph IV Disputes: Expert Insights on Hatch-Waxman Litigation Strategies for Brand Names and Generics
May 1, 2008
8th Annual Maximizing Pharmaceutical Patent Life Cycles Conference American Conference Institute
October 24, 2007
Where Pharmaceutical Science and Patent Law Battle: Polymorphs and the Solid State D.C. Bar Intellectual Property Law Section
March 20, 2007
Latest Legislative and Judicial Updates Impacting US Pharma Industry 5th Annual Pharmaceutical Patent Life Cycles Conference
January 20, 2006
Hatch-Waxman Update: (I) Declaratory Judgment Actions, and (II) In re Petering 6th Annual Conference Maximizing Pharmaceutical Patent Life Cycles
October 18, 2005
Claim Construction of Pharmaceutical Patents 4th Annual Pharmaceutical Patent Life Cycle Conference
April 19, 2005
Best Practices for Litigating Polymorph and Pharmaceutical Patent Cases 3rd Annual Polymorphism & Crystallization Conference
November 15-17, 2004
Exclusivity and FDA Barriers to Market Entry in the U.S. EuroLegal Conference - 3rd Annual Pharmaceutical Patent Life Cycles
July 5-6th, 2004
Medicare Prescription Drug, Improvement, and Modernization Act of 2003 Law Seminars International program: Running the Race with Biotechnology
May 3-4, 2004
Best Practices in Pharmaceutical Patent Litigation Polymorphism & Crystallization Forum 2004: Science, Technology & Intellectual Property
April 26, 2004
Changes in Patent Practice Brought About By the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 Law Seminars International Program:Running the Race with Biotechnology
March 8-9, 2004
Invoking a Patent Challenge: Paragraph IV Certifications and Beyond 4th National Maximizing Pharmaceutical Patent Life Cycles Conference
January 27, 2004
Strategies For Licensing Your Way Out of Trouble American Conference Institute
November 11, 2003
Developments In Patent Law: Written Description and Best Mode National Forum on Biotechnology and Pharmaceuticals Conference
April 8, 2003
Exclusivity: Who Can Stay and Who Can Play Legal Strategies for Maximizing Pharmaceutical Patent Life Cycles Conference
April 1, 2003
In The News
Fitzpatrick Listed as a Band 1 Intellectual Property Firm in Chambers USA 2010 Chambers USA
June, 2010
Fitzpatrick, Cella, Harper & Scinto Named the 2010 “Best US IP Law Firm” International Legal Alliance Summit and Awards
June 8, 2010
Life Sciences Elite Intellectual Asset Management Magazine
April 2010
ACQ Law Awards ACQ Finance Magazine
November 2009
Seven Fitzpatrick Lawyers Listed as Best IP Lawyers in America 2010 Best Lawyers in America 2010
October 2009
Nine Fitzpatrick Partners Named As Top New York Intellectual Property Litigators in the 2009 issue of Super Lawyers: New York Metro Edition Super Lawyers: New York Metro Edition
October 2009
Intellectual Property in the Life Sciences Industry Corporate INTL
October 2009
Fitzpatrick Listed as a Band 1 Intellectual Property Firm in Chambers USA 2009 Chambers USA 2009
June 2009
Fitzpatrick Named as Leading New York Firm Practical Law Company's Which Lawyer? Yearbook
April 2009
Managing Intellectual Property North American IP Awards Managing Intellectual Property
March 30, 2009
Fitzpatrick Ranked in Top Five in IP Today's Annual Survey Intellectual Property Today
March 2009
Fitzpatrick Listed as a Tier 1 Intellectual Property Firm in Chambers Global 2009 Chambers Global 2009
January 2009
Seven Fitzpatrick Lawyers Listed as Best IP Lawyers in America 2009 Best Lawyers in America 2009
October 2008
Nine Fitzpatrick Partners Named As Top New York Intellectual Property Litigators in the 2008 issue of Super Lawyers: New York Metro Edition Super Lawyers: New York Metro Edition 2008
October 2008
Pharmaceutical IP Litigation Firm of the Year Managing Intellectual Property North American IP Awards
April 3, 2008
Fitzpatrick Ranked in Top Five in IP Today's Annual Survey Intellectual Property Today
March 2008
Fitzpatrick Listed as a Tier 1 Intellectual Property Firm in Chambers Global 2008 Chambers Global 2008
January 2008
Seven Fitzpatrick Lawyers Listed as Best IP Lawyers in America 2008 Best Lawyers in America 2008
October 2007
Nine Fitzpatrick Partners Named As Top New York Intellectual Property Litigators in the 2007 issue of Super Lawyers: New York Metro Edition Super Lawyers: New York Metro Edition 2007
September 2007
Fitzpatrick Attorneys Featured in New York Magazine Profile New York Magazine
July 2-9, 2007
Fitzpatrick Named as Leading New York Firm PLC Which Lawyer Yearbook 2007
May 2007
Fitzpatrick Listed as Tier 1 Intellectual Property Firm in Chambers Global 2007 Chambers Global 2007
January 2007
Fitzpatrick Listed as Top IP Firm with Five Mentions on Who Protects IP America Survey IP Law & Business
November 2006
Seven Fitzpatrick Lawyers Listed as Best IP Lawyers in America 2007 Best Lawyers in America 2007
October 2006
Two Fitzpatrick Lawyers Named Best of the Best 2006 The US Best of the Best
July 2006
Fitzpatrick Named as a Leading Firm in Chambers Global 2006 Chambers Global The World's Leading Lawyers for Business
2006
Fitzpatrick Ranked #7 Most Diverse Law Firm in New York The New York Law Journal's Book of Lists 2006
March 2006
Fitzpatrick Named as Leading New York Firm PLC Which Lawyer Yearbook 2006
February 2006
Fitzpatrick Named as a Leading Firm in Chambers Global 2006 Chambers Global
2006
Two New Fitzpatrick Partners Named in 2006January 1, 2006
Fitzpatrick Ranked Leading Firm in PLC Which Lawyer 2005/2006 PLC Which Lawyer 2005/2006
December 2005
Eight Fitzpatrick Lawyers Listed as Best IP Lawyers in America 2006, The Most Listed for IP in New York Best Lawyers in America 2006
September 2005
Fitzpatrick Ranked in Band 1 in 2005 Chambers USA Survey Chambers USA: America's Leading Lawyers for Business
May 25, 2005
Seven Fitzpatrick Lawyers Included on List of Best IP Lawyers in America Best Lawyers in America
2005-2006
Fitzpatrick Lawyer Selected By Chambers USA As Leader In the Field of Intellectual Property Chambers USA
February 3, 2005
Fitzpatrick Receives 2004 MCCA Thomas L. Sager AwardNovember/December 2004
Fitzpatrick's Pharmaceutical Practice Highlighted in Crain's New York Business Article Crain's New York Business
September 27, 2004
Fitzpatrick Client, Novartis, Wins Consent Judgment in Lamisil® Litigation IP Law Bulletin
September 3, 2004
Fitzpatrick Ranked #4 In 2004 Diversity ScorecardJune 2004
Bob Baechtold Named Best of the Best 2004 Euromoney Expert Guide
April 2004
Fitzpatrick Ranked as Leading Firm in 2004 Chambers USA Survey Chambers USA: Leading Business Lawyers
April 21, 2004
Seven Fitzpatrick Lawyers Listed as Best IP Lawyers in America Best Lawyers in America
2003-2004
Fitzpatrick Attorney Named To Top Global Counsel List Global Counsel 3000; Intellectual Property
2004-2005
Fitzpatrick Elects Three New PartnersJanuary 1, 2004
Fitzpatrick Associate Featured in NYLJ Article New York Law Journal
December 12, 2003
Fitzpatrick Ranked # 10 In 2002 Diversity ScorecardDecember 2003
Fitzpatrick's Pharmaceutical Practice Highlighted in IP Law & Business ArticleNovember 2003
Partner Leisa M. Smith Receives The Network Journal's 40-Under Forty Achievement AwardJune 19, 2003
Fitzpatrick Announces Two New PartnersJanuary 1, 2003
Fitzpatrick Ranked As A Top U.S. Intellectual Property Law Firm Chambers Global: World's Leading Lawyers 2003 and Chambers USA: America's Leading Business Lawyers
2003-2004
Three New Fitzpatrick Partners Named 2002January 2002
Partner Bob Baechtold Ranked a Tier 1 IP Lawyer in New York Chambers Global: World's Leading Lawyers 2003 and Chambers USA: America's Leading Business Lawyers 2003-2004
2003-2004
Six Fitzpatrick Lawyers Ranked as World's Leading Patent Experts 2003 Guide to the World's Leading Patent Law Experts
2003
Fitzpatrick Receives 2002 MCCA Thomas L. Sager AwardOctober 16, 2002
Robert L. Baechtold Voted Best of the Best 2002 Best of the Best
2002
Fitzpatrick, Cella Recognized for 20 Years of Service to Improving JusticeDecember 13, 2001
Four Partners Nominated to the International Who's Who of Business Lawyers2001
California Office Relocates to Larger Quarters2001
Robert L. Baechtold Elected President-elect of the Federal Circuit Bar Association2001
Bob Baechtold Named "THE BEST OF THE BEST 2000"2000
Press Releases
Fitzpatrick, Cella, Harper & Scinto Honored For Industry Excellence in Intellectual Property by Chambers & Partners Chambers & Partners USA 2010
June 14, 2010
Best US IP Law Firm International Legal Alliance Summit and Awards 2010
June 8, 2010
Life Science/Biotech & Pharmaceutical IP Litigation Firm of the Year Managing Intellectual Property
April 16, 2010
Life Science/Biotech & Pharmaceutical IP Litigation Firm of the Year MANAGING INTELLECTUAL PROPERTY
April 16, 2010
Fitzpatrick, Cella, Harper & Scinto Elects Jason M. Okun as New PartnerJanuary 4, 2010
Fitzpatrick, Cella, Harper, & Scinto Named “Decade Award Winner” in Legal Writing by the Burton Foundation Burton Foundation
December 16, 2009
Fitzpatrick, Cella Listed as a Tier One Intellectual Property Firm Institutional Investor's 2010 Benchmark Litigation Guide
December 8, 2009
Fitzpatrick named Patent Law Firm of the Year: North America ACQ Finance Magazine
December 01, 2009
Fitzpatrick, Cella, Harper & Scinto's New York Headquarters RelocatesSeptember 14, 2009
Fitzpatrick Cella Successfully Defends Blockbuster Drug Benicar®August 7, 2009
Fitzpatrick, Cella, Harper & Scinto Honored by Chambers & Partners in Tier 1 for New York Intellectual Property Law Firms Chambers & Partners USA 2009
June 16, 2009
Pharmaceutical IP Litigation Firm of the Year Managing Intellectual Property
March 30, 2009
Colleen Tracy Named as Fitzpatrick's Managing PartnerMarch 19, 2009
New Partners NamedJanuary 6, 2009
Fitzpatrick, Cella, Harper & Scinto Ranked #1 in Intellectual Property Chambers USA 2008
June 16, 2008
Fitzpatrick Prevails in Patent Infringement SuitJune 21, 2007
Fitzpatrick, Cella, Harper & Scinto Ranked #1 in Intellectual PropertyJune 18, 2007
Fitzpatrick Cella Announces Win in Trusopt® Patent-Infringement CaseApril 2, 2007
Fitzpatrick Cella Elects Five New PartnersJanuary 1, 2007
Fitzpatrick, Cella, Harper & Scinto Ranked #1 in IPJune 7, 2006
Fitzpatrick Commences Legal Action on Behalf of Clients Eisai Co. and Eisai Inc. Over Aricept ANDA FilingDecember 7, 2005
Fitzpatrick Commences Legal Action on Behalf of Client AstraZeneca Over Seroquel PatentNovember 14, 2005
Fitzpatrick, Cella, Harper & Scinto Receives Minority Corporate Counsel Association's Thomas L. Sager Diversity AwardOctober 28, 2004
Fitzpatrick Commences Legal Action on Behalf of Clients Wyeth and Altana Pharma Over Protonix ANDA FilingMay 25, 2004
Fitzpatrick Elects Three PartnersJanuary 5, 2004
Fitzpatrick, Cella Commences Legal Action on Behalf of Client Eisai Over Aciphex ANDA FilingsDecember 9, 2003
John D. Murnane Joins Fitzpatrick's Patent PracticeJune 2, 2003
Fitzpatrick Elects Two PartnersJanuary 6, 2003
Fitzpatrick Receives Thomas L. Sager Diversity AwardOctober 17, 2002
Area Leader/Chair: Robert L. Baechtold
ATTORNEYS IN THIS PRACTICE AREA
Partners
Tara A. Byrne
Nicholas M. Cannella
John D. Carlin
Dominick A. Conde
Donald J. Curry
Daniel S. Glueck
Bruce C. Haas
Edmund J. Haughey
Nicholas N. Kallas, Ph.D.
Steven C. Kline
Leisa Smith Lundy
Raymond R. Mandra
Michael P. McGraw
John D. Murnane
Jason M. Okun
Lisa Barons Pensabene
Marc J. Pensabene
Lawrence S. Perry
Filko Prugo
Scott K. Reed
Henry J. Renk
Simon D. Roberts
Joshua I. Rothman
Peter Saxon
Diego Scambia
Gregory B. Sephton, Ph.D.
Brian V. Slater
William E. Solander
Colleen Tracy
Ha Kung Wong
Counsel
Stephen K. Sullivan, Ph.D.
Associates
Dennis C. Aeling
Melissa Alberts
Will C. Autz
Christopher P. Borello
Thomas Burns
Lucian C. Chen
Patrick L. Chen
Jeffrey R. Colin
Robert J. Czarnecki, Jr.
Fiona E. Darkin
Joshua A. Davis
Ralph A. Dengler
Joseph B. Divinagracia
Damien N. Dombrowski
Susanne L. Flanders
Michael Enzo Furrow, Ph.D.
Joanna L. Garelick
Kimberley A. Gavin, Ph.D
Dennis Gregory
Sachin Gupta
Vishal C. Gupta
Margaret A. Hallet
Court D. Heinle
Lindsay H. Hersh
Jessica Hiney
Elizabeth F. Holowacz
Anna Huang
Cheney H. Huang
Charlotte Jacobsen
David M. Kelly
Steven S. Kim
Allyson King
John W. Kirkland
Leslie Kushner, Ph.D.
Adam C. LaRock
Dana Lau, Ph.D.
Jason A. Leonard
Jeffrey S. Levitt
Christopher E. Loh
Kristina M. Mahoney
Leila Kaplus Marcovici
Gabrielle Markeson
Brendan Mee
Frederick C. Millett
Daniel J. Minion
Victoria Silcott Molenda
Erica L. Norey
Todd M. Nosher
Brendan M. O'Malley, Ph.D.
Brian D. O'Reilly
Daniel O’Boyle
Jason E. O’Leary
Monica Parvulescu
Robert W. Pierson Jr.
Thomas J. Puppa
Margaret A. Radzik
Aaron J. Rugh
Alicia Russo
Robert S. Schwartz, Ph.D.
Christina Schwarz
Kenneth J. Szeto
Jamar W. Tyndale
Damond E. Vadnais
Sujatha Vathyam, Ph.D.
Chandrika Vira
Kelly L. Wines
Lori A. Wolfe
Vanessa Yen
Of Counsel
Robert L. Baechtold
Charles P. Baker
